Stroke and late-onset Alzheimer's disease (AD) are risk factors for each other; the
comorbidity of these brain disorders in aging individuals represents a significant challenge …

Glutamate is an essential excitatory neurotransmitter in the central nervous system, playing
an indispensable role in neuronal development and memory formation. The dysregulation of …

Background To determine the protective effects of memantine on cognitive function in
patients receiving whole-brain radiotherapy (WBRT). Methods Adult patients with brain …

A simple, primary amine bearing a C10H15 alkyl residue was found to display potent anti-
Influenza A properties in 1964. 1 Soon thereafter, antiviral activity of this amine was found …

β‐amyloid (Aβ) is widely accepted to be one of the major pathomechanisms underlying
Alzheimer's disease (AD), although there is presently lively debate regarding the relative …

In many neurologic disorders, injury to neurons may be caused at least in part by
overstimulation of receptors for excitatory amino acids, including glutamate and aspartate …

Alzheimer's disease (AD) is a progressive neurodegenerative disease, characterized by the
loss of memory, multiple cognitive impairments and changes in the personality and …

An estimated 20% of patients with cancer will develop brain metastases. Approximately
200,000 individuals in the United States alone receive whole-brain radiotherapy (WBRT) …

Alzheimer's disease (AD) is the most prevalent chronic neurodegenerative disease. Current
approved therapies are symptomatic treatments having some effect on cognitive function …

This review describes the preclinical mechanisms that may underlie the increased
therapeutic benefit of combination therapy—with the N-methyl-d-aspartate receptor …